FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
Want to see FBLG full AI Analyst Report?
FBLG Stock Chart & Stats
$1.53
-$0.09(-3.98%)
At close: 4:00 PM EST
$1.53
-$0.09(-3.98%)
Day’s Range― - ―
52-Week Range$0.77 - $15.54
Previous CloseN/A
Volume56.64K
Average Volume (3M)978.93K
Market Cap
$4.01M
Enterprise Value$2.43M
Total Cash (Recent Filing)$1.48M
Total Debt (Recent Filing)$2.48M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Jul 30, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.22
Shares Outstanding5,208,915
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.37
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$8.00Price Target Upside422.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Nasdaq Listing Compliance RestoredRegaining Nasdaq compliance preserves public market access and liquidity for shareholders, enabling ongoing capital raises and secondary market trading. This structural outcome reduces immediate delisting risk and sustains a platform for financing and investor visibility over the coming months.
Meaningful Reduction In Total DebtSubstantially lower debt reduces interest and covenant pressure, improving financial flexibility for a clinical‑stage biotech. The decline in leverage meaningfully lowers short‑term insolvency risk and gives management more optionality to allocate scarce capital to R&D and operations.
Expanded At‑the‑market Equity CapacityAn expanded ATM facility is a durable financing tool that provides flexible, on‑demand access to equity capital to fund trials and operations. For a cash‑burning clinical developer, this structured capacity supports runway planning and reduces reliance on single large financings.
Bears Say
No Revenue; Widening Net LossesAs a clinical‑stage biotech without commercialization, persistent and growing net losses reflect ongoing R&D and operating spend without offsetting sales. This structural gap erodes equity, extends time to profitability, and sustains long‑term funding dependency until therapies reach market.
Heavy And Worsening Cash BurnConsistently large negative operating and free cash flows indicate the company consumes significant cash to advance trials. This durable cash burn increases the frequency and magnitude of needed financings, constraining long‑term R&D planning and elevating dilution risk absent material revenue or partnership milestones.
Dependence On Equity Financing And Dilution RiskRepeated reliance on ATM facilities and recent public offerings signals structural dependence on equity markets for liquidity. For a pre‑revenue biotech, this creates ongoing dilution risk and execution uncertainty if markets turn unfavourable or sufficient demand for new issuance evaporates.
FibroBiologics, Inc. News
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.77 and its highest was $15.54 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $4.01M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 39 days.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Apr 30, 2026. The company reported -$1.255 earnings per share for the quarter, beating the consensus estimate of -$1.334 by $0.079.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate is -0.83.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 5,208,915 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$1.255 in its last earnings report, beating expectations of -$1.334. Following the earnings report the stock price went up 10.606%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Currently, no hedge funds are holding shares in FBLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
$8.00
▲(422.88% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Curis
―
Synlogic
―
Lexaria Bioscience
―
Processa Pharmaceuticals
―